ClinicalTrials.gg
CompletedNCT04935320Updated Feb 19, 2025

Comparison of Blood Levels of HTL0016878 From an Oral Capsule and an Oral Solution

A Phase 1 interventional study of HTL0016878.HCl Solution 10 mg and HTL0016878.Citrate Capsule 10 mg in Healthy Subjects, sponsored by Nxera Pharma UK Limited. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-19.

Sponsored by Nxera Pharma UK Limited · Phase 1, Interventional, and Treatment

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

This is a randomised, open-label, 3-period, crossover single dose study to assess the relative bioavailability of two formulations of HTL0016878: an oral solution of HCl salt form (the reference product) and an oral capsule containing citrate salt (the test product); and of the effect of food on the pharmacokinetics of the capsule formulation.

Read the detailed description

Fifteen healthy male or female subjects will be enrolled. Each subject will have 3 study sessions and receive a single oral dose of 10 mg HTL0016878 on Day 1 of each study session. Subjects will receive the HTL0016878.HCl oral solution in the fasted state in 1 session, and the HTL0016878.citrate capsule, in the fasted state and after a high-fat meal, respectively, in the other 2 sessions. Each subject will be randomised to 1 of 3 treatment sequences (5 subjects to each sequence). There will be a washout of at least 10 days between doses. Subjects will be screened within 35 days before their first dose of HTL0016878. In each study session, subjects will be resident on the ward from the day before dosing (Day -1) until completion of procedures 72 h after their dose (Day 4). Subjects will return for a follow up visit 10-13 days after their final dose of trial medication.

02

Conditions studied

  • Healthy Subjects

Keywords

  • Relative Bioavailability
03

In context

Lead sponsor

Nxera Pharma UK Limited is the lead sponsor of 14 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male or females, aged 18-50 years
  2. Female subjects must agree to use highly effective
  3. Weigh 60 kg or more, with a in the range 18.0-30.0 kg/m2
  4. Sufficient intelligence to understand the nature of the trial
  5. Willingness to give written consent to participate
  6. Agree to use the contraception requirements of the trial
  7. Agree not to donate blood or blood products during the study and for up to 3 months after the administration of the trial medication
  8. Willingness to give written consent to have data entered into The Overvolunteering Prevention System

Exclusion criteria

Exclusion Criteria:

  1. Woman who is pregnant or lactating
  2. abnormal history, physical findings, , or laboratory values
  3. Presence or history of acute or chronic illness, or mental health problem
  4. Impaired neurological, endocrine, thyroid, cardiovascular, respiratory, gastrointestinal, hepatic or renal function, diabetes mellitus, coronary heart disease, or history of any psychiatric disorder or psychotic mental illness
  5. Cancer during the 5 years before screening
  6. Supine blood pressure and heart rate outside the ranges: 90-140 mm Hg systolic and 50-90 mm Hg diastolic blood pressure; heart rate 45-80 beats/min
  7. Supine (QTcF) outside the ranges 300-450 msec (men) and 300-470 msec (women)
  8. Personal or family history of long QT syndrome or family sudden death
  9. Positive test for , or
  10. , alanine aminotransferase, gamma glutamyl transferase or total levels > 1.5 times the
  11. \< 80 mL/min/1.73 m2
  12. Presence or history of drug or alcohol abuse in the past 5 years; or regular intake of more than 21 units of alcohol weekly (for men) or 14 units of alcohol weekly (for women); or use of cigarettes, tobacco and/or nicotine-containing products during the 3 months before dosing
  13. Evidence of drug abuse or positive alcohol or cotinine test results
  14. Positive pregnancy test
  15. Habitual and heavy consumption of caffeinated beverages
  16. Use of a prescription or over-the-counter medicine, any herbal remedy, or nutritional supplement
  17. Receipt of a vaccine against COVID-19 in the 14 days before dosing
  18. Received within 6 weeks prior to Screening
  19. History of severe allergies
  20. Use of any drugs that are inhibitors of CYP2D6
  21. Poor metaboliser of CYP2D6
  22. History of epilepsy or seizures
  23. Any disease associated with cognitive impairment and/or psychosis
  24. Suicidal thoughts or ideation, or insomnia
  25. Any history of mental illness (including anxiety, depression), which required medical intervention
  26. Presence or history of severe adverse reaction to any drug
  27. Surgery or medical condition that might affect absorption of medicines
  28. Receipt of an product as part of another clinical trial within the 3 months before dosing in this study
  29. Receipt of HTL0016878 in a previous clinical trial
  30. Loss of more than 400 mL blood during the 3 months before dosing
  31. Unwilling to eat a high-fat breakfast
  32. Possibility that the volunteer will not cooperate with the requirements of the protocol
  33. Objection by GP to volunteer entering trial
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Oral Solution Fasted

    HTL0016878.HCl 10 mg, single dose, oral solution, fasted

    Drug: HTL0016878.HCl Solution 10 mg

  • Experimental
    Oral Capsule Fasted

    HTL0016878.citrate 10 mg, single dose, oral capsule, fasted

    Drug: HTL0016878.Citrate Capsule 10 mg

  • Experimental
    Oral Capsule Fed

    HTL0016878.citrate 10 mg, single dose, oral capsule, fed

    Drug: HTL0016878.Citrate Capsule 10 mg

Interventions

  • DrugHTL0016878.HCl Solution 10 mg

    Oral solution fasted

  • DrugHTL0016878.Citrate Capsule 10 mg

    Oral capsule fed or fasted

06

What researchers measure

Primary outcomes

  1. Concentration of HTL0016878 in plasma Cmax

    Pharmacokinetics

    Time frame: 0-72 hours

  2. Concentration of HTL0016878 in plasma AUC

    Pharmacokinetics

    Time frame: 0-72 hours

Secondary outcomes

  1. Treatment Emergent Adverse Events

    Safety and Tolerability

    Time frame: Baseline up to 13 days post-dose

07

Study locations

1 site
  • Hammersmith Medicines Research Ltd (HMR)
    London, NW10 7EW, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2021 to primary completion in Oct 2021, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2021
First posted
Jun 23, 2021
StartActual
Jul 29, 2021
Primary completionActual
Oct 29, 2021
CompletionActual
Oct 29, 2021
Last update
Feb 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04935320
Lead sponsor
Nxera Pharma UK Limited
Responsible party
Sponsor
First posted
Jun 23, 2021
Start date
Jul 29, 2021
Primary completion
Oct 29, 2021
Completion
Oct 29, 2021
Last update
Feb 19, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion